Monoclonal Gammopathy of Undetermined Significance (MGUS) | Zendy

Viera Sandecká | Zendy; Luděk Pour | Zendy; Zdeněk Adam | Zendy; Marta Krejčí | Zendy; Martin Štork | Zendy; Sabina Ševčı́ková | Zendy; Zdeněk Král | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Author(s) -

Viera Sandecká,

Luděk Pour,

Zdeněk Adam,

Marta Krejčí,

Martin Štork,

Sabina Ševčı́ková,

Zdeněk Král

Publication year - 2018

Publication title -

klinicka onkologie

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.204

H-Index - 13

eISSN - 1802-5307

pISSN - 0862-495X

DOI - 10.14735/amko2018270

Subject(s) - monoclonal gammopathy of undetermined significance , multiple myeloma , medicine , macroglobulinemia , bone marrow , lymphoproliferative disorders , immunoglobulin light chain , serum protein electrophoresis , waldenstrom macroglobulinemia , pathology , gammopathy , asymptomatic , monoclonal , hematology , immunology , gastroenterology , lymphoma , antibody , monoclonal antibody

Monoclonal gammopathy of undetermined significance (MGUS) is one of the most prevalent premalignant conditions associated with a risk of malignant transformation to multiple myeloma (MM) or other forms of lymphoproliferative disorders with risk of progression of approximately 1% per year. IgG and IgA MGUS are precursor conditions of multiple myeloma (MM), whereas light-chain MGUS is a precursor condition of light chain MM. IgM MGUS is a precursor condition of Waldenström macroglobulinemia (MW) or other lymphoproliferative diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research